The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Positron emission tomography molecular imaging for drug development
Open accessAbstract
Human in vivo molecular imaging with positron emission tomography (PET) enables a new kind of ‘precision pharmacology’, able to address questions central to drug development. Biodistribution studies with drug molecules carrying positron‐emitting radioisotopes can test whether a new chemical entity reaches a target tissue compartment (such as the brain) in sufficient amounts to be pharmacologically active. Competition studies, using a radioligand that binds to the target of therapeutic interest with adequate specificity, enable direct assessment of the relationship between drug plasma concentration and target occupancy. Tailored radiotracers can be used to measure relative rates of biological processes, while radioligands specific for tissue markers expected to change with treatment can provide specific pharmacodynamic information. Integrated application of PET and magnetic resonance imaging (MRI) methods allows molecular interactions to be related directly to anatomical or physiological changes in a tissue. Applications of imaging in early drug development can suggest approaches to patient stratification for a personalized medicine able to deliver higher value from a drug after approval. Although imaging experimental medicine adds complexity to early drug development and costs per patient are high, appropriate use can increase returns on R and D investment by improving early decision making to reduce new drug attrition in later stages. We urge that the potential value of a translational molecular imaging strategy be considered routinely and at the earliest stages of new drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citationPET/MRI: Paving the Way for the Next Generation of Clinical Multimodality Imaging Applications
Pichler, B. J., Kolb, A., Nägele, T., & Schlemmer, H.-P. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.061853 · Cited by 418
Abanades, S., van der Aart, J., Barletta, J. A., Marzano, C., Searle, G. E., Salinas, C. A., Ahmad, J. J., Reiley, R. R., Pampols-Maso, S., Zamuner, S., et al. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.175 · Cited by 61
Self-citation
Cited by
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
Drug discovery and development: Role of basic biological research
Mohs, R. C., & Greig, N. H. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.10.005 · Cited by 673
Photocatalysis in the Life Science Industry
Candish, L., Collins, K. D., Cook, G. C., Douglas, J. J., Gómez-Suárez, A., Jolit, A., & Keess, S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00416 · Cited by 428
A General Copper‐Mediated Nucleophilic 18F Fluorination of Arenes
Tredwell, M., Preshlock, S. M., Taylor, N. J., Gruber, S., Huiban, M., Passchier, J., Mercier, J., Génicot, C., & Gouverneur, V. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201404436 · Cited by 388
Self-citation
Metadata
- Authors
- Matthews, P. M., Rabiner, E. A., Passchier, J., & Gunn, R. N.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2012-01-06
- Volume
- 73
- Issue
- 2
- Pages
- 175-186
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1546274595
- Cited by
- 320
- References
- 3
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Positron emission tomography molecular imaging for drug development. https://app.cochat.ai/papers/10.1111/j.1365-2125.2011.04085.x
- The paper
- Matthews, P. M., Rabiner, E. A., Passchier, J., & Gunn, R. N. (2012). Positron emission tomography molecular imaging for drug development. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2011.04085.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.